| 13:00 |
Commercialisation through externalisation: creating new opportunities through strategic partnerships
In order to bring therapies and medicines to patients with unmet needs, forming new strategic partnerships, creating new out-licensing agreements, and even spinning out assets to form new companies, is key. This panel will discuss expanding pipelines and gaining partners through strategically deprioritising assets, either through forming out-licensing agreements or building new companies around a single core asset, along with experience shared from panellists, challenges, and the benefit of biotech’s scouting for assets.
- How to maximise the value of the alliance for both partners, and reduce the risk of failure
- Spotting key new opportunities and when to know to spin out and asset, including key risks and challenges
- Lessons learned and future outlook
Moderator: Madeleine Armstrong, News Editor, Evaluate
Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
Jorge Santos da Silva , CEO, MoonLake Immunotherapeutics
Catherine Pickering, CEO, iOnctura
Dominique Bridon, CEO, Diaccurate SA
    
|
| 16:30 |
Navigating Biotech Funding Dynamics: Is Flat the New Up? Shifts in Public and Private Finance
While the S&P index of biotech stocks stabilised in mid-2022 and showing signs of timidly increasing, funding challenges still remain in the public markets and the trickle-down effect remains in the private markets- particularly in later stage funding. A panel of expert investors in private, crossover and public markets debate and discuss:
- Perspectives on the public markets and impacts its having on private funding
- What are later-stage investors advising their portfolio and growing later stage biotechs?
- Strategies to navigate the current volatile market
Moderator: William Hicks, Co-chair Securities Capital Markets Group, Mintz
Tom Burt, Partner, Sofinnova Partners
Wouter Joustra, General Partner, Forbion
Alexandra Taracanova, Director, Strategic Partnerships, RTW Investments
   
|
